What's Happening?
Bristol Myers Squibb has announced preliminary Phase 3 findings from its ADEPT program, evaluating KarXT (xanomeline and trospium chloride) for the treatment of psychosis associated with Alzheimer’s disease. Data from the 12-week open-label period of the ADEPT-1
study and the 52-week open-label extension (OLE) ADEPT-3 study were presented. In both studies, KarXT treatment was associated with observed improvements in clinician-observed scores for hallucinations and delusions, as well as overall disease severity. The medication was generally well tolerated, with no new safety signals identified. These initial findings represent the first disclosure of clinical data from the Phase 3 ADEPT program, which remains ongoing. The ADEPT-1 study is a global, randomized, double-blind, placebo-controlled relapse prevention study, while ADEPT-3 assesses long-term safety and tolerability.
Why It's Important?
These preliminary findings are significant because there are currently no FDA-approved treatments specifically for psychosis associated with Alzheimer's disease. Psychosis, including hallucinations and delusions, affects 30-50% of Alzheimer's patients and is linked to faster cognitive decline, increased caregiver burden, and higher rates of institutionalization. Current management often relies on off-label antipsychotics, which carry significant safety concerns for older adults with dementia. The positive results for KarXT, showing improvements in symptoms and good tolerability, offer a potential new therapeutic option for a condition that profoundly impacts patients and their families. This could address a critical unmet medical need and improve the quality of life for a vulnerable patient population.
What's Next?
The ADEPT trials are ongoing, and data from the double-blind treatment periods in all ADEPT studies remain blinded. Bristol Myers Squibb anticipates sharing additional results as the program advances. The next steps will involve the unblinding and analysis of the full efficacy and safety data from the double-blind portions of the ADEPT-1, ADEPT-2, and ADEPT-4 studies, which evaluate acute efficacy. If these results are positive, Bristol Myers Squibb will likely pursue regulatory approval from the FDA for KarXT as a treatment for psychosis associated with Alzheimer's disease. Successful approval would make KarXT the first dedicated treatment for this condition, potentially transforming patient care.
Beyond the Headlines
The development of KarXT for Alzheimer's-related psychosis highlights the growing focus on addressing the neuropsychiatric symptoms of neurodegenerative diseases, which often contribute significantly to patient suffering and caregiver strain. Beyond the immediate clinical benefits, a successful treatment could reduce the societal and economic burden associated with managing these complex symptoms, including decreased hospitalizations and improved quality of life for caregivers. This research also underscores the importance of targeting specific pathways involved in behavior and cognition, as KarXT operates through central cholinergic muscarinic receptor modulation. The potential approval of such a drug could also stimulate further research into other neuropsychiatric manifestations of Alzheimer's and related dementias, fostering innovation in an area with substantial unmet needs.













